SUTRO BIOPHARMA, INC. Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 19 rows, 19 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-03-07: Reporting owner Borgman Anne Elizabeth; Form 3; Security No securities beneficially held; Transaction Holding.
- 2021-11-22: Reporting owner Hunter Heidi; Form 3; Security No securities beneficially held; Transaction Holding.
- 2021-08-11: Reporting owner Chung Jane; Form 3; Security No securities beneficially held; Transaction Holding.
- 2020-12-01: Reporting owner Wigginton Jon Marc; Form 3; Security No securities beneficially held; Transaction Holding.
STRO insiders stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
No transaction of this security type is retained for this issuer, so the price history carries no markers. The chart is the same one every issuer renders.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-03-07 holding as of filing | Borgman Anne Elizabeth Officer (Chief Medical Officer) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2023-03-07 | |
| 2021-11-22 holding as of filing | Hunter Heidi Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2021-11-22 | |
| 2021-08-11 holding as of filing | Chung Jane Officer (Chief Commercial Officer) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2021-08-11 | |
| 2020-12-01 holding as of filing | Wigginton Jon Marc Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2020-12-01 | |
| 2020-01-08 holding as of filing | PANEK JAMES P Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2020-01-08 | |
| 2019-06-26 holding as of filing | MATSUI CONNIE Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2019-06-26 | |
| 2018-11-13 holding as of filing | Sharp Shalini Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-11-13 | |
| 2018-09-26 holding as of filing | Worsley Stephen Officer (Chief Business Officer) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | Petree Daniel H Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | MOLINA ARTURO MD Officer (Chief Medical Officer) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | Lobacki Joseph M Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | JANNEY DANIEL Director, 10% Owner | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | Hallam Trevor Officer (Chief Science Officer) | 3 | Series D Shares Derivative · Direct | Holding | no price filed | 2018-09-26 | ||
| 2018-09-26 holding as of filing | Freund John Gordon Director, 10% Owner | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | FITZPATRICK LINDA A Officer (Chief People & Comm. Officer) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | Dybbs Michael Director | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | Shabbir Anik Officer (Chief Technical Ops. Officer) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | NOHRA GUY P | JANNEY DANIEL | Alta Partners VIII, L.P. | Alta Partners Management VIII, LLC | CHAMPSI FARAH 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 | |
| 2018-09-26 holding as of filing | ALBINI EDWARD C Officer (CFO and Secretary) | 3 | No securities beneficially held Non-derivative · Direct | Holding | 0 owned after | no price filed | 2018-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |